
|Articles|August 1, 2004
Supplements and Featured Publications
- Newsletter - Inflammation, Metabolic Syndrome, and CV Risk Reduction
- Volume 10
- Issue 2 Metab
CE / CME
Advertisement
Articles in this issue
over 21 years ago
Commentaryover 21 years ago
Post Testover 21 years ago
Faculty Disclosure Statementover 21 years ago
Metabolic syndrome: A new target of therapy?Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Mirvetuximab Soravtansine Demonstrates Promising Efficacy, Safety in Platinum-Resistant Recurrent Ovarian Cancer
2
Ocrelizumab Leads to Lower Hospitalization Rates Compared to Rituximab in MS
3
Zanubrutinib Shows Similar Efficacy but Better Safety Than VEN–I in Frontline CLL
4
The Changing Treatment Landscape of IPF and PPF: Toby Maher, MD, PhD
5













































